Pindolol Use for Treatment-Refractory Panic Disorder

References (14)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Publishing, Inc; 2013.
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. PubMed CrossRef
3. Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415–424. PubMed CrossRef
4. Roy-Byrne PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety. 1994;1(4):151–160. PubMed CrossRef
5. Freire RC, Zugliani MM, Garcia RF, et al. Treatment resistant panic disorder: a systematic review. Expert Opin Pharmacother. 2016;17(2):159–168. PubMed CrossRef
6. Perna G, Caldirola D. Management of treatment resistant panic disorder. Curr Treat Options Psychiatry. 2017;4(4):371–386. PubMed CrossRef
7. Joseph SS, Lynham JA, Molenaar P, et al. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1- adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003;368(6):496–503. PubMed CrossRef
8. Newman-Tancredi A, Chaput C, Gavaudan S, et al. Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology. 1998;18(5):395–398. PubMed CrossRef
9. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets. 2006;7(2):139–147. PubMed CrossRef
10. Whale R, Terao T, Cowen P, et al. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2010;24(4):513–520. PubMed CrossRef
11. Kleeblatt J, Betzler F, Kilarski LL, et al. Efficacy of off label augmentation in unipolar depression: a systematic review of the evidence. Eur Neuropsychopharmacol. 2017;27(5):423–441. PubMed CrossRef
12. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20(5):556–559. PubMed CrossRef
13. Rabiner EA, Gunn RN, Castro ME, et al. beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 2000;23(3):285–293. PubMed CrossRef
14. Fernandes E, Gomes A, Costa D, et al. Pindolol is a potent scavenger of reactive nitrogen species. Life Sci. 2005;77(16):1983–1992. PubMed CrossRef